Kweichow Moutai Presents Chinese Enterprise’s ESG Insights at 2025 WEF
Wang Li, General Manager of Kweichow Moutai Group, China's top liquor company, was invited to participate in the 2025 World Economic Forum (WEF) Annual Meeting, which officially opened recently, and shared the Moutai solutions on topics such as ESG practices, green and low-carbon development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124612942/en/
Wang Li, General Manager of Kweichow Moutai Group, presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon. (Photo: Business Wire)
At the 2025 Davos-Tencent Finance Vision Dinner, Wang explained the ESG development based on Moutai's practices. She said that Moutai adheres to long-termism and high-quality development, integrates the ESG concept into the entire production and operation process. By pursuing sustainable development from three dimensions: harmonious coexistence with nature, sharing of social value, and modernization of self-governance, Moutai accumulates momentum and advantages for future development.
Besides, Wang Li presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon as well. She said that Moutai liquor is the result of adhering to harmonious coexistence between mankind and nature. Kweichow Moutai Group insists on leveraging the innovative power of green technology to support the company's green development, focusing on "energy saving, carbon reduction, emission reduction, and efficiency improvement" to achieve "greening level improvement of the main value chain".
Through the resource utilization, greening and high-end development of the by-products in the liquor industry, Moutai has realized the utilization of its by-products. Looking to the future, Moutai will be committed to applying more innovative power and methods of green technology to maintain the characteristics of its products.
Furthermore, Wang proposed Moutai's carbon reduction solution at the First Movers Coalition Leadership Meeting. Wang said, “The accurate management of the whole chain is an important feature of Moutai's carbon emission management. Moutai accounts for the carbon footprint of the whole life cycle of its products and has formulated targeted programs for the transformation of the energy structure, the reduction and greening of packaging materials, etc.”
Moutai also pays attention to the recycling of post-drinking packages, and plans to start post-drinking package recycling in China's provincial capitals in 2025, with the goal of reducing the carbon emissions of the whole industrial chain by 20% by 2030.
During the WEF, Wang Li will also take part in the “China Night” dialogue, sharing Moutai's wisdom with Chinese and foreign experts on the thinking of Chinese enterprises in coping with the age of intelligence and the shaping of the international image of Chinese enterprises.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250124612942/en/
Contacts
Eason Zhou
Email: evisionsinfo@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom